New Delhi, July 15 -- India's pharmaceutical industry is collating product data to mount a response to the government's notice on drug brand name extensions.

To compile the database, pharma associations such as the Indian Drug Manufacturers Association (IDMA) have asked manufacturers to submit details of their affected product portfolios. The information sought includes brand names, active ingredients, dosage forms, strengths, the likely business impact, and sales data, even for FY26.

The Drugs Controller General of India (DCGI) sent a communication to pharma associations last week, warning them of strict action against the practice of extending a primary brand name to treat a completely different illness.

"Concerns have been raised th...